ORGS: Orgenesis Inc. Stock

by  •  • Comments Off on ORGS: Orgenesis Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 16.90
Enterprise Value ($M) 38.35
Book Value ($M) -20.98
Book Value / Share -0.61
Price / Book -0.81
NCAV ($M) -31.46
NCAV / Share -0.92
Price / NCAV -0.54

Profitability (mra)
Return on Invested Capital (ROIC) -33.80
Return on Assets (ROA) -0.59
Return on Equity (ROE) -0.93

Liquidity (mrq)
Quick Ratio 0.25
Current Ratio 0.25

Balance Sheet (mrq) ($M)
Current Assets 4.08
Assets 14.55
Liabilities 35.53
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.53
Operating Income -52.20
Net Income -55.36
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -14.84
Cash from Investing -3.71
Cash from Financing 13.62

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Safier Jacob 15.60
09-07 13G/A New Dimensions Trading 15.40 245.61

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-15 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2024-04-15 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2024-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2024-04-15 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 7,648 26,571 28.78
2024-04-17 11,793 77,005 15.31
2024-04-16 23,655 122,329 19.34
2024-04-15 7,536 108,899 6.92

(click for more detail)

Similar Companies
ONCY – Oncolytics Biotech Inc. ONVO – Organovo Holdings, Inc.
ORGO – Organogenesis Holdings Inc. ORMP – Oramed Pharmaceuticals Inc.
OTLK – Outlook Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io